Baseline demographics and clinical characteristics
| Characteristic . | R2 cohort (n = 44) . |
|---|---|
| Age, median (range), y | 16 (9-30) |
| <18 y | 31 (70) |
| Male sex | 29 (66) |
| Performance status, median (range) | |
| Lansky, n = 26∗ | 100 (70-100) |
| Karnofsky, n = 18† | 100 (80-100) |
| Stage at initial diagnosis | |
| II | 21 (48) |
| III | 7 (16) |
| IV | 16 (36) |
| Response to first-line therapy | |
| Primary refractory‡ | 24 (55) |
| Relapsed§ | 20 (45) |
| 3-12 mo | 14 (32) |
| ≥12 mo | 6 (14) |
| Prior auto-HCT | 0 |
| Prior BV | 0 |
| Prior systemic therapy | 44 (100) |
| OEPA/COPDAC | 20 (46) |
| OEPA | 6 (14) |
| ABVE-PC | 6 (14) |
| ABV/COPP | 4 (9) |
| ABVD | 4 (9) |
| ABVE | 2 (5) |
| Other | 2 (5) |
| Prior radiation therapy | 16 (36) |
| B symptoms or extranodal disease at relapse, extensive disease (RT contraindicated), or relapse in a prior radiation field | 28 (64) |
| Bone marrow involvement | 5 (11) |
| Stage IV disease at relapse | 16 (36) |
| Characteristic . | R2 cohort (n = 44) . |
|---|---|
| Age, median (range), y | 16 (9-30) |
| <18 y | 31 (70) |
| Male sex | 29 (66) |
| Performance status, median (range) | |
| Lansky, n = 26∗ | 100 (70-100) |
| Karnofsky, n = 18† | 100 (80-100) |
| Stage at initial diagnosis | |
| II | 21 (48) |
| III | 7 (16) |
| IV | 16 (36) |
| Response to first-line therapy | |
| Primary refractory‡ | 24 (55) |
| Relapsed§ | 20 (45) |
| 3-12 mo | 14 (32) |
| ≥12 mo | 6 (14) |
| Prior auto-HCT | 0 |
| Prior BV | 0 |
| Prior systemic therapy | 44 (100) |
| OEPA/COPDAC | 20 (46) |
| OEPA | 6 (14) |
| ABVE-PC | 6 (14) |
| ABV/COPP | 4 (9) |
| ABVD | 4 (9) |
| ABVE | 2 (5) |
| Other | 2 (5) |
| Prior radiation therapy | 16 (36) |
| B symptoms or extranodal disease at relapse, extensive disease (RT contraindicated), or relapse in a prior radiation field | 28 (64) |
| Bone marrow involvement | 5 (11) |
| Stage IV disease at relapse | 16 (36) |
Data are given as number (percentage) unless stated otherwise.
ABV, doxorubicin, bleomycin, and vinblastine; ABVD, doxorubicin, bleomycin, vinblastine, and dacarbazine; ABVE, doxorubicin, bleomycin, vincristine, and etoposide; ABVE-PC, doxorubicin, bleomycin, vincristine, etoposide, prednisone, and cyclophosphamide; COPDAC, cyclophosphamide, vincristine, prednisone, and dacarbazine; COPP, cyclophosphamide, vincristine, procarbazine, and prednisone; OEPA, vincristine, etoposide, prednisone, doxorubicin.
Patients aged ≤16 years.
Patients aged >16 years.
Never achieved remission or who achieved remission to prior therapy, then experienced progression <3 months after completion of that therapy.
Achieved remission to prior therapy, then experienced recurrent disease ≥3 months after completion of that therapy.